Billy Sinclair

Learn More
When using cephalopods as experimental animals, a number of factors, including morality, quality of information derived from experiments, and public perception, drives the motivation to consider welfare issues. Refinement of methods and techniques is a major step in ensuring protection of cephalopod welfare in both laboratory and field studies. To this end,(More)
Nautilus species are the only remaining cephalopods with an external shell. Targeted heavily by the shell trade across their distribution area, these species have a poorly known population structure and genetics. Molecular techniques have been used to assess levels of inter- and intra-population genetic diversity in isolated populations of Nautilus in the(More)
Use of medications was investigated in 819 nine year old children living in Dunedin. Twenty-four percent of the cohort (199 children) were given medications during the week prior to interview, mainly on prescription (68%). The majority of medicines used were said to be for respiratory illnesses and oral antibiotics represented a high proportion of(More)
Patient understanding of the nature of asthma and of its management was assessed using an interviewer administered questionnaire in a community sample of asthmatics identified through prescriptions at randomly selected Dunedin city pharmacies. Of 135 subjects whose histories, and lung function data where available, were consistent with asthma, 20 did not(More)
This study examines the trends in drug treatment and costs of hypertension in a cohort of 1600 adult Aucklanders between 1982 and 1987. In 1987 prices the average daily cost of antihypertensive drug treatment per person increased from 42 cents to 74 cents over the five year period. The increase in cost seen in antihypertensive therapy in this cohort is(More)
This paper examines the pattern of drug treatment of hypertension in Auckland in the period 1982 to 1987 using data from a representative sample of the adult population interviewed in 1982 and followed up in 1987. In 1982 the age standardised prevalence of antihypertensive treatment for people aged 40-64 years was 12.2% (95%Cl 10.4, 14.0) and in 1987 it was(More)
  • 1